Zake-Don't think we have been at the same parties
I would have remembered if you had the privilege of "intercoursing" with me...
As for INSM, I think the issues are rather simple:
Which will win the race-the need for cash or the science results?
I think this company will never market another product itself-that's what DNA is for. This company is now a research division of DNA, but it must raise its own funds in the near term. Dilutive stock offering or debt on unfavorable terms if science is not encouraging; less dilutive offering or favorable debt, or even early DNA opt-in, if results are favorable.
It shall be a topsy-turvy ride for next 24 months. But I will still be here, hopefully not to be 'intercoursed' again by INSM.